• PF-573228 FAK Inhibitor in Mechanobiology

  2026-08-10

  PF-573228 provides a practical pharmacological switch for testing how FAK controls adhesion, migration, angiogenesis, and stiffness-responsive differentiation. This workflow connects the LAMB1–FAK–MEK1/2 dentinogenesis model with cancer and endothelial assays while emphasizing dose control, pathway-specific readouts, and reproducible substrate handling.

• Ibuprofen: From COX Inhibition to Assay Design

  2026-08-09

  Ibuprofen is more than a conventional NSAID in experimental biology: its COX activity, exposure behavior, and p53-linked cellular effects must be interpreted together. This guide presents an assay-first framework for studying inflammation, apoptosis, and proliferation while drawing practical lessons from drug–protein binding research.

• CDCA–FXR–KLF11 Signaling in Contrast AKI

  2026-08-08

  A 2026 study identifies an FXR–KLF11 transcriptional pathway that protects against contrast-induced acute kidney injury by restraining JAK2/STAT3 signaling. Using mouse and HK-2 cell models, the work connects Chenodeoxycholic Acid-mediated nuclear receptor activation with reduced tubular injury, inflammation, and apoptosis, while also defining important preclinical limitations.

• Anisomycin and JNK: From Stress Signals to Cell Fate

  2026-08-07

  Anisomycin is a potent JNK agonist for dissecting stress signaling, apoptosis, and context-dependent cell fate. This article connects cancer-cell perturbation studies with a 2025 social-memory study to show how temporal assay design can improve mechanistic interpretation.

• FLT3-TAZ Signaling Drives Drug Resistance in BP-CML: New Ins

  2026-08-07

  Shin et al. reveal that FLT3 signaling activates a JAK-STAT3-TAZ-TEAD-CD36 axis, promoting blast phase CML drug resistance independent of BCR::ABL1 mutations. Their work establishes FLT3 as a prognostic marker and therapeutic target, informing new strategies for overcoming TKI resistance in advanced CML.

• Rotigotine Hydrochloride: Neurogenic Bladder & Dopaminergic

  2026-08-06

  Explore how Rotigotine hydrochloride, a potent dopamine D2/D3 receptor agonist, modulates neurogenic bladder function and dopaminergic signaling in Parkinson's disease research. This article delivers unique mechanistic insights and protocol guidance for advanced preclinical models.

• WZ4003: Advanced NUAK1/2 Inhibitor Workflows & Troubleshooti

  2026-08-06

  WZ4003 is a highly selective NUAK1/2 inhibitor optimized for dissecting cell migration, proliferation, and tau phosphorylation in cancer and neurodegenerative disease models. This guide translates the latest reference breakthroughs into stepwise protocols, comparative insights, and troubleshooting strategies for robust, reproducible results.

• Technical Use of Hoechst 33342/PI Double Staining Kit (K2237

  2026-08-05

  The Hoechst 33342/PI Double Staining Kit provides researchers with a rapid, dual-fluorescence assay for distinguishing viable, apoptotic, and necrotic cells based on nuclear chromatin condensation and membrane integrity. It is optimized for microscopy-based analysis in basic research settings and is not suitable for diagnostic or clinical use.

• Chronic Stress, Mitochondrial Dysfunction, and MnTBAP Rescue

  2026-08-05

  This study demonstrates that chronic unpredictable mild stress (CUMS) induces depression-like behavior in rats by disrupting brain mitochondrial function and elevating proinflammatory cytokines. Intracerebroventricular administration of MnTBAP, a mitochondrial-targeted antioxidant, significantly ameliorated these effects, underscoring a mechanistic link between mitochondrial dysfunction, neuroinflammation, and depression.

• N-MYC/eIF4G1 Axis Controls inv(16) AML Survival via CBFβ-SMM

  2026-08-04

  The referenced study uncovers N-MYC as a critical driver of cell survival in inv(16) acute myeloid leukemia (AML), acting through transcriptional regulation of eIF4G1. By demonstrating that the CBFβ-SMMHC fusion protein maintains leukemogenesis via the N-MYC/eIF4G1 pathway, the work provides new mechanistic insight and research directions for targeted intervention in AML.

• Cycloheximide in Fibrosis & Protein Turnover: Mechanisms and

  2026-08-04

  Explore cycloheximide as a protein biosynthesis inhibitor in fibrosis and protein turnover studies. This in-depth article goes beyond apoptosis assays to reveal new mechanistic insights and protocol guidance, integrating recent breakthroughs in TGF-β signaling and practical research workflows.

• Rotigotine Hydrochloride: Mechanistic Insight and Strategy i

  2026-08-03

  This in-depth thought-leadership article bridges mechanistic understanding and strategic guidance for translational researchers leveraging Rotigotine hydrochloride, a dopamine D2/D3 receptor agonist, in Parkinson’s disease models. Addressing both motor and non-motor disease spectra, including lower urinary tract dysfunction, it synthesizes preclinical evidence, protocol recommendations, and competitive positioning, while clearly differentiating its scope from standard product summaries.

• Tumor-Targeted PAD4 Inhibition: Suppressing H3cit and NETs I

  2026-08-03

  This study demonstrates that meta-phenylboronic acid-modified PAD4 inhibitors, such as Compound 5i TFA, achieve highly selective tumor targeting and robust inhibition of the PAD4–H3cit–NETs pathway in neutrophils. The findings highlight a novel strategy for reducing tumor growth and metastasis by modulating tumor immune microenvironments while minimizing systemic toxicity.

• Senolytic Actions of L. plantarum DS0037 Exosome-like Nanove

  2026-08-02

  This study demonstrates that exosome-like nanovesicles (ELNs) derived from Lactobacillus plantarum DS0037 selectively induce apoptosis in senescent cells while modulating gene expression to improve skin cell function. These findings highlight the potential of microbial ELNs as targeted senotherapeutics and anti-aging cosmetic agents.

• Mtb Hijacks BMX Kinase to Inhibit Lysosomal Acidification

  2026-08-01

  This study elucidates how Mycobacterium tuberculosis (Mtb) deploys the secreted protein Chp2 to enhance BMX kinase-mediated phosphorylation of the host V-ATPase E1 subunit, thereby inhibiting lysosomal acidification and supporting intracellular survival. The findings identify BMX kinase as a pivotal regulator in the host-pathogen interface, highlighting a novel therapeutic target for host-directed tuberculosis interventions.

445 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page